Chadds Ford, PA, United States of America

May Grace E Venturanza

This inventor holds 4 USPTO granted patents and 1 published patent application. Top assignee: Incyte Corporation. Active years: 2022-2026.

USPTO Granted Patents = 4 

% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2022-2026

Loading Chart...
4 patents (USPTO):Explore Patents

Title: May Grace E Venturanza: Innovator in Dermatological Treatments

Introduction

May Grace E Venturanza is a prominent inventor based in Chadds Ford, PA (US). She has made significant contributions to the field of dermatology, particularly in the treatment of atopic dermatitis. With a total of 4 patents to her name, her work focuses on innovative formulations that aim to improve patient care.

Latest Patents

One of her latest patents includes a formulation of ruxolitinib designed for the reduction of itch in patients suffering from atopic dermatitis. This disclosure outlines methods for alleviating itch and treating patients by administering a topical cream containing either 0.75% or 1.5% ruxolitinib two times per day. This formulation represents a significant advancement in the management of atopic dermatitis, providing relief to those affected by this condition.

Career Highlights

May Grace E Venturanza is currently employed at Incyte Corporation, where she continues to develop innovative solutions in dermatological treatments. Her expertise and dedication to research have positioned her as a key player in her field.

Collaborations

She collaborates with notable colleagues, including Kang Sun and Michael D Howell, to further enhance the impact of her work. These partnerships are essential in driving forward the research and development of effective treatments.

Conclusion

May Grace E Venturanza's contributions to dermatology through her innovative patents and collaborative efforts highlight her commitment to improving patient outcomes. Her work continues to pave the way for advancements in the treatment of atopic dermatitis.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…